4D Molecular Therapeutics, Inc.4D Molecular Therapeutics, Inc.4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪1.34 B‬USD
−2.73USD
‪−100.84 M‬USD
‪20.72 M‬USD
‪43.64 M‬
Beta (1Y)
2.02

About 4D Molecular Therapeutics, Inc.

CEO
David H. Kirn
Headquarters
Emeryville
Employees (FY)
147
Founded
2013
ISIN
US35104E1001
FIGI
BBG00QG40R88
4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. The firm also offers product candidates focused on large market ophthalmology, pulmonology, and cardiology. The company was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of FDMT is 26.76 USD — it has decreased by 3.39% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange 4D Molecular Therapeutics, Inc. stocks are traded under the ticker FDMT.
4D Molecular Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for 4D Molecular Therapeutics, Inc. has a max estimate of 82.00 USD and a min estimate of 34.00 USD.
FDMT earnings for the last quarter are −0.24 USD whereas the estimation was −0.61 USD which accounts for 60.86% surprise. Estimated earnings for the next quarter are −0.73 USD. See more details about 4D Molecular Therapeutics, Inc. earnings.
4D Molecular Therapeutics, Inc. revenue for the last quarter amounts to ‪20.20 M‬ USD despite the estimated figure of ‪8.07 M‬ USD. In the next quarter revenue is expected to reach ‪2.40 M‬ USD.
Yes, you can track 4D Molecular Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, FDMT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade 4D Molecular Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
FDMT reached its all-time high on Feb 11, 2021 with the price of 55.11 USD, and its all-time low was 5.32 USD and was reached on Jun 16, 2022.
See other stocks reaching their highest and lowest prices.
As of Apr 12, 2024, the company has 147.00 employees. See our rating of the largest employees — is 4D Molecular Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. 4D Molecular Therapeutics, Inc. EBITDA is ‪−99.31 M‬ USD, and current EBITDA margin is −516.90%. See more stats in 4D Molecular Therapeutics, Inc. financial statements.